175 related articles for article (PubMed ID: 9648381)
1. [Influence of weight and distribution of adipose tissue in functional hyperandrogenism].
Pasquali R; Vicennati V; Gambineri A
Contracept Fertil Sex; 1998 May; 26(5):372-5. PubMed ID: 9648381
[TBL] [Abstract][Full Text] [Related]
2. The impact of obesity on reproduction in women with polycystic ovary syndrome.
Pasquali R; Gambineri A; Pagotto U
BJOG; 2006 Oct; 113(10):1148-59. PubMed ID: 16827825
[TBL] [Abstract][Full Text] [Related]
3. Ethinylestradiol-drospirenone, flutamide-metformin, or both for adolescents and women with hyperinsulinemic hyperandrogenism: opposite effects on adipocytokines and body adiposity.
Ibáñez L; de Zegher F
J Clin Endocrinol Metab; 2004 Apr; 89(4):1592-7. PubMed ID: 15070917
[TBL] [Abstract][Full Text] [Related]
4. Adiponectin is independently associated with insulin sensitivity in women with polycystic ovary syndrome.
Spranger J; Möhlig M; Wegewitz U; Ristow M; Pfeiffer AF; Schill T; Schlösser HW; Brabant G; Schöfl C
Clin Endocrinol (Oxf); 2004 Dec; 61(6):738-46. PubMed ID: 15579189
[TBL] [Abstract][Full Text] [Related]
5. Serum visfatin in relation to insulin resistance and markers of hyperandrogenism in lean and obese women with polycystic ovary syndrome.
Kowalska I; Straczkowski M; Nikolajuk A; Adamska A; Karczewska-Kupczewska M; Otziomek E; Wolczynski S; Gorska M
Hum Reprod; 2007 Jul; 22(7):1824-9. PubMed ID: 17582143
[TBL] [Abstract][Full Text] [Related]
6. Obesity, body composition and metabolic disturbances in polycystic ovary syndrome.
Svendsen PF; Nilas L; Nørgaard K; Jensen JE; Madsbad S
Hum Reprod; 2008 Sep; 23(9):2113-21. PubMed ID: 18556679
[TBL] [Abstract][Full Text] [Related]
7. Obesity and the polycystic ovary syndrome.
Gambineri A; Pelusi C; Vicennati V; Pagotto U; Pasquali R
Int J Obes Relat Metab Disord; 2002 Jul; 26(7):883-96. PubMed ID: 12080440
[TBL] [Abstract][Full Text] [Related]
8. Prevalence and characteristics of the polycystic ovary syndrome in overweight and obese women.
Alvarez-Blasco F; Botella-Carretero JI; San Millán JL; Escobar-Morreale HF
Arch Intern Med; 2006 Oct; 166(19):2081-6. PubMed ID: 17060537
[TBL] [Abstract][Full Text] [Related]
9. Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels.
Panidis D; Farmakiotis D; Rousso D; Kourtis A; Katsikis I; Krassas G
Fertil Steril; 2008 Apr; 89(4):899-906. PubMed ID: 17980364
[TBL] [Abstract][Full Text] [Related]
10. Endocrine-metabolic effects of the treatment with pioglitazone in obese patients with polycystic ovary syndrome.
Garmes HM; Tambascia MA; Zantut-Wittmann DE
Gynecol Endocrinol; 2005 Dec; 21(6):317-23. PubMed ID: 16390779
[TBL] [Abstract][Full Text] [Related]
11. Obesity and the polycystic ovary syndrome.
Martínez-Bermejo E; Luque-Ramírez M; Escobar-Morreale HF
Minerva Endocrinol; 2007 Sep; 32(3):129-40. PubMed ID: 17912153
[TBL] [Abstract][Full Text] [Related]
12. Effects of metformin therapy on hyperandrogenism in women with polycystic ovarian syndrome.
Kazerooni T; Dehghan-Kooshkghazi M
Gynecol Endocrinol; 2003 Feb; 17(1):51-6. PubMed ID: 12724019
[TBL] [Abstract][Full Text] [Related]
13. A randomized, 48-week, placebo-controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study.
Hoeger KM; Kochman L; Wixom N; Craig K; Miller RK; Guzick DS
Fertil Steril; 2004 Aug; 82(2):421-9. PubMed ID: 15302293
[TBL] [Abstract][Full Text] [Related]
14. Detecting insulin resistance in polycystic ovary syndrome: purposes and pitfalls.
Legro RS; Castracane VD; Kauffman RP
Obstet Gynecol Surv; 2004 Feb; 59(2):141-54. PubMed ID: 14752302
[TBL] [Abstract][Full Text] [Related]
15. Metformin administration is more effective when non-obese patients with polycystic ovary syndrome show both hyperandrogenism and hyperinsulinemia.
Genazzani AD; Lanzoni C; Ricchieri F; Baraldi E; Casarosa E; Jasonni VM
Gynecol Endocrinol; 2007 Mar; 23(3):146-52. PubMed ID: 17454168
[TBL] [Abstract][Full Text] [Related]
16. [Early metabolic abnormalities--insulin resistance, hyperinsulinemia, impaired glucose tolerance and diabetes, in adolescent girls with polycystic ovarian syndrome].
Otto-Buczkowska E; Jarosz-Chobot P; Deja G
Przegl Lek; 2006; 63(4):234-8. PubMed ID: 17080748
[TBL] [Abstract][Full Text] [Related]
17. Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome.
Wu J; Zhu Y; Jiang Y; Cao Y
Gynecol Endocrinol; 2008 Jul; 24(7):392-8. PubMed ID: 18608522
[TBL] [Abstract][Full Text] [Related]
18. Role of obesity and adiposity in polycystic ovary syndrome.
Diamanti-Kandarakis E
Int J Obes (Lond); 2007 Nov; 31 Suppl 2():S8-13; discussion S31-2. PubMed ID: 17968437
[TBL] [Abstract][Full Text] [Related]
19. Predictive value of glucose-insulin ratio in PCOS and profile of women who will benefit from metformin therapy: obese, lean, hyper or normoinsulinemic?
Onalan G; Goktolga U; Ceyhan T; Bagis T; Onalan R; Pabuçcu R
Eur J Obstet Gynecol Reprod Biol; 2005 Dec; 123(2):204-11. PubMed ID: 16316811
[TBL] [Abstract][Full Text] [Related]
20. Polycystic ovarian syndrome: the commonest cause of hyperandrogenemia in women as a risk factor for metabolic syndrome.
Diamanti-Kandarakis E; Christakou C; Kandarakis H
Minerva Endocrinol; 2007 Mar; 32(1):35-47. PubMed ID: 17353865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
